Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.
Palandri F, Palumbo GA, Bonifacio M, Elli EM, Tiribelli M, Auteri G, Trawinska MM, Polverelli N, Benevolo G, Tieghi A, Cavalca F, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Venturi M, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Branzanti F, Vianelli N, Cavo M, Heidel F, Iurlo A, Breccia M. Palandri F, et al. Cancers (Basel). 2023 Oct 17;15(20):5027. doi: 10.3390/cancers15205027. Cancers (Basel). 2023. PMID: 37894394 Free PMC article.
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study.
Palandri F, Rossi E, Auteri G, Breccia M, Paglia S, Benevolo G, Elli EM, Cavazzini F, Binotto G, Tieghi A, Tiribelli M, Heidel FH, Bonifacio M, Pugliese N, Caocci G, Crugnola M, Mendicino F, D'Addio A, Tomassetti S, Martino B, Polverelli N, Ceglie S, Mazzoni C, Mullai R, Ripamonti A, Garibaldi B, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Palumbo GA, Andriani A, Cavo M, Latagliata R, De Stefano V. Palandri F, et al. Among authors: heidel fh. Cancers (Basel). 2023 Jul 21;15(14):3706. doi: 10.3390/cancers15143706. Cancers (Basel). 2023. PMID: 37509367 Free PMC article.
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.
Wolleschak D, Mack TS, Perner F, Frey S, Schnöder TM, Wagner MC, Höding C, Pils MC, Parkner A, Kliche S, Schraven B, Hebel K, Brunner-Weinzierl M, Ranjan S, Isermann B, Lipka DB, Fischer T, Heidel FH. Wolleschak D, et al. Among authors: heidel fh. Haematologica. 2014 Jun;99(6):e90-3. doi: 10.3324/haematol.2014.104331. Epub 2014 Mar 14. Haematologica. 2014. PMID: 24633870 Free PMC article. No abstract available.
Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.
Perner F, Schnöder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, Frey S, Polanetzki A, Fahldieck C, Schönborn U, Schraven B, Isermann B, Fischer T, Heidel FH. Perner F, et al. Among authors: heidel fh. Leukemia. 2016 Apr;30(4):991-5. doi: 10.1038/leu.2015.218. Epub 2015 Aug 5. Leukemia. 2016. PMID: 26242463 No abstract available.
Gain of function in Jak2V617F-positive T-cells.
Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schnöder TM, Just S, Heidel FH, Schlüter D. Nishanth G, et al. Among authors: heidel fh. Leukemia. 2017 Apr;31(4):1000-1003. doi: 10.1038/leu.2017.6. Epub 2017 Jan 11. Leukemia. 2017. PMID: 28074070 No abstract available.
Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T, Heidel FH. Schnöder TM, et al. Among authors: heidel fh. J Cancer Res Clin Oncol. 2017 May;143(5):807-820. doi: 10.1007/s00432-017-2354-1. Epub 2017 Feb 23. J Cancer Res Clin Oncol. 2017. PMID: 28233092
149 results